key: cord-0993465-sl688zvl authors: Chaudhry, Rama; Sreenath, K; Batra, Priyam; Vinayaraj, EV; Rathor, Nisha; Saikiran, KVP; Aravindan, Ajisha; Singh, Vishwajeet; Brijwal, Megha; Soneja, Manish; Verma, Nishant; Subramanium, Rajeshwari; Singh, Urvashi B.; Guleria, Randeep title: Atypical bacterial co‐infections among patients with COVID‐19: A study from India date: 2021-09-15 journal: J Med Virol DOI: 10.1002/jmv.27324 sha: e6bc7c11a680809d80d225da6239099f791ef09f doc_id: 993465 cord_uid: sl688zvl Emerging evidence shows co‐infection with atypical bacteria in coronavirus disease 2019 (COVID‐19) patients. Respiratory illness caused by atypical bacteria such as Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila may show overlapping manifestations and imaging features with COVID‐19 causing clinical and laboratory diagnostic issues. We conducted a prospective study to identify co‐infections with SARS‐CoV‐2 and atypical bacteria in an Indian tertiary hospital. From June 2020 to January 2021, a total of 194 patients with laboratory‐confirmed COVID‐19 were also tested for atypical bacterial pathogens. For diagnosing M. pneumoniae, a real‐time polymerase chain reaction (PCR) assay and serology (IgM ELISA) were performed. C. pneumoniae diagnosis was made based on IgM serology. L. pneumophila diagnosis was based on PCR or urinary antigen testing. Clinical and epidemiological features of SARS‐CoV‐2 and atypical bacteria‐positive and ‐negative patient groups were compared. Of the 194 patients admitted with COVID‐19, 17 (8.8%) were also diagnosed with M. pneumoniae (n = 10) or C. pneumoniae infection (n = 7). Confusion, headache, and bilateral infiltrate were found more frequently in the SARS CoV‐2 and atypical bacteria co‐infection group. Patients in the M. pneumoniae or C. pneumoniae co‐infection group were more likely to develop ARDS, required ventilatory support, had a longer hospital length of stay, and higher fatality rate compared to patients with only SARS‐CoV‐2. Our report highlights co‐infection with bacteria causing atypical pneumonia should be considered in patients with SARS‐CoV‐2 depending on the clinical context. Timely identification of co‐existing pathogens can provide pathogen‐targeted treatment and prevent fatal outcomes of patients infected with SARS‐CoV‐2 during the current pandemic. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is identified for the first time at the end of 2019 in Wuhan, China, and is responsible for a contagious respiratory disease known as Coronavirus disease . 1 The virus has spread rapidly in many parts of the world, and as of August 20, 2021 , there have been 209.87 million confirmed cases of COVID-19, including 4400 thousand deaths worldwide. 2 In India, 32.35 million confirmed cases and 433 thousand deaths were reported as of August 20, 2021 . 3 Clinical presentations of COVID-19 vary from asymptomatic infection to fatal disease with acute respiratory distress syndrome (ARDS) and multiorgan failure. 4 Bacterial co-infections associated with COVID-19 have been frequently reported; however, their proportions are very low compared to previous influenza pandemics. Lansbury et al. found that 7% of hospitalized patients with COVID-19 had bacterial co-infections, with a higher rate of 14% in intensive care unit (ICU) patients. 5 Co-infection with SARS-CoV-2 and atypical bacteria such as Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae has been identified in few studies. [6] [7] [8] Due to overlapping clinical presentations and image features, it is difficult to distinguish between SARS-CoV-2 and bacteria causing atypical pneumonia. Besides this, it is unclear whether co-infection with atypical bacteria can cause worse clinical outcomes in COVID-19 patients. Here, we conducted a prospective study to determine the prevalence of co-infection related to atypical bacteria in patients admitted with COVID-19 in an Indian tertiary hospital. We also describe the demographic and clinical features, laboratory parameters, complications, and clinical outcomes of such co-infections. Patient data were mainly collected using a standard questionnaire or extracted from electronic medical records. The following data were mainly collected: hospital admission details, demographics (age, gender, and presence or absence of underlying health conditions), clinical and laboratory data, chest X-ray, details of ICU admission, mechanical ventilation, antibiotic treatment, and fatal outcome. and 20 μl of proteinase K (20 mg/ml) were added to 200 μl of the respiratory sample, and the mixture was incubated at 56°C for 10 min. Following manual lysis, the samples were placed on the QIAGEN QIAcube instrument for automated nucleic acid extraction using the QIAGEN protocol. The extracted nucleic acids were then tested for Legionella spp. and M. pneumoniae using two previously published real-time PCR assays. 9,10 Samples with a cycle threshold (C t ) value of <40 were determined as positive. Whenever a positive result was observed, the testing was repeated in triplicates for confirmation. A specimen was considered real-time PCR-positive for Legionella spp. or M. pneumoniae if the sample tested positive in at least two of the three repeats. Each real-time PCR assay is reported to have a specificity of 100% and a sensitivity (limit of detection [LOD] ) of 20 fg per reaction (data not shown). 2.5 | Urinary antigen testing (UAT) for L. pneumophila serogroup 1 L. pneumophila antigen in urine was detected using BinaxNOW Legionella urinary antigen ICT kit (Alere), specific for Lp1. The manufacturer's instructions were followed for performing the UAT. The assay offers a sensitivity of 95% and specificity of 95% for Lp1. 2.6 | Serology for M. pneumoniae and C. pneumoniae The serologic diagnosis was made based on commercial ELISA kits (NovaLisa, NovaTec Immunodiagnostica GmbH). These kits were routinely used to detect serum M. pneumoniae IgM (MYCM0350) and C. pneumoniae IgM (CHLM0510) in clinical practice at our facility. Briefly, these assays used single 1:101 dilutions of serum in sample buffer and included cut-off calibrators in determining samples as positive or negative. As control of assay performance, a positive and negative control were also included on each plate per assay. The manufacturer's instructions were followed for performing the assays and interpreting antibody determinations. A value of >11 NTU (NovaTec units) obtained in a single determination was considered positive. These tests offer a sensitivity of 94.4% and 90% and specificity of >95% and 99% for M. pneumoniae and C. pneumoniae, respectively. The diagnosis of COVID-19 was based on positivity by RT-PCR or CB-NAAT or rapid antigen test on oropharyngeal/nasal swab sam- Categorical variables were expressed as numbers (percentages) and compared using the χ 2 test or Fisher's exact test. Continuous variables were shown as median (interquartile ranges) and compared between two independent groups using the t test or Wilcoxon ranksum test as per the distribution of the data. Statistical significance was defined at a p < 0.05. Statistical software, STATA/SE version 14.2 (StataCorp LP), was used for all the analysis. Current literature shows co-infection with SARS-CoV-2 and other respiratory pathogens, and the data is still evolving. 5, 13, 14 In the present study, we report co-infections due to atypical bacteria in Bacterial co-infections in SARS-CoV-2 may play a role in the prognosis of the disease and result in significant morbidity and mortality. 5, 13 In the present study, there were a significantly higher proportion of patients with M. pneumoniae or C. pneumoniae co-infection need mechanical ventilation support and were likely to develop complications. Similar findings are also reported in a study from Europe. 27 Presently, no specific treatment exists for COVID-19, and supportive care is the mainstay. Treatment with hydroxychloroquine, remdesivir, tocilizumab, and lopinavir/ritonavir have been used in certain situations. 6, 28 The drug of choice for atypical pneumonia include fluoroquinolones, macrolides, and tetracyclines. 15 Our study has a few limitations. All COVID-19 patients admitted to our facility were not simultaneously tested for atypical pathogens. Therefore, the true incidence of co-infection remains unclear. A lower respiratory tract specimen (e.g., sputum, BAL, endotracheal wash, lung tissue) is the suitable sample for Legionella diagnosis; however, collection of invasive respiratory samples in COVID patients was restricted to prevent aerosol-generating procedures that pose a significant risk to health care staff and patients. We could not use molecular methods to diagnose C. pneumoniae infections, for which we could rely only on serology. Lastly, the use of serology for diagnosis of M. pneumoniae and C. pneumoniae is fraught with problems related to low specificity resulting from cross-reactivity and persistence of antibodies from prior infection. Furthermore, a single IgM is not reliable, but rather needs to be interpreted in conjunction with acute and convalescent IgG measurement, which is often challenging to obtain. A new coronavirus associated with human respiratory disease in China Ministry of Health and Family Welfare | Home Clinical features of patients infected with 2019 novel coronavirus in Wuhan Co-infections in people with COVID-19: a systematic review and meta-analysis Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19 and Mycoplasma pneumoniae in the USA Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature SARS-CoV-2 and Legionella co-infection in a person returning from a Nile cruise Clinical application of a multiplex real-time PCR assay for simultaneous detection of Legionella species, Legionella pneumophila, and Legionella pneumophila serogroup 1 Evaluation of three real-time PCR assays for detection of Mycoplasma pneumoniae in an outbreak investigation Clinical management of COVID-19, interim guidance 27 Clinical Management Protocol: COVID-19 Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division) Version Co-infections: potentially lethal and unexplored in COVID-19 Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis Mycoplasma pneumoniae from the respiratory tract and beyond Association of mortality and recent Mycoplasma pneumoniae infection in COVID-19 patients A 49-year-old woman co-infected with SARS-COV-2 and mycoplasma-a case report Co-detection of respiratory pathogens in patients hospitalized with Coronavirus viral disease-2019 pneumonia Sixty-eight consecutive patients assessed for COVID-19 infection: experience from a UK regional infectious diseases unit. Influenza Other Respir Viruses Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Coinfection and other clinical characteristics of COVID-19 in children Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area Legionella pneumophila in patients with pneumonia at a referral hospital Coinfections with other respiratory pathogens among patients with COVID-19 Clinical features and outcomes of adult COVID-19 patients co-infected with Mycoplasma pneumoniae Detection of Mycoplasma pneumoniae and Legionella pneumophila in patients having community-acquired pneumonia: a multicentric study from New Delhi, India Co-infection of Chlamydia pneumoniae and Mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features COVID-19, modern pandemic: a systematic review from front-line health care providers' perspective Mycoplasma pneumoniae and its role as a human pathogen Atypical bacterial co-infections among patients with COVID-19: A study from India The authors declare that there are no conflict of interests. The Ethical Committee of the AIIMS has provided approval for this study (Ref. No.: IEC-287/17.04.2020, RP-35/2020). All the data generated or analyzed during this study are included in this article. http://orcid.org/0000-0002-7381-1504Ajisha Aravindan http://orcid.org/0000-0003-1071-8596Manish Soneja http://orcid.org/0000-0002-8619-7929